Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy

• Main Authors: Inja Waldhauer (Author), Valeria Gonzalez-Nicolini (Author), Anne Freimoser-Grundschober (Author), Tapan K Nayak (Author), Linda Fahrni (Author), Ralf J. Hosse (Author), Danny Gerrits (Author), Edwin J. W. Geven (Author), Johannes Sam (Author), Sabine Lang (Author), Esther Bommer (Author), Virginie Steinhart (Author), Elisabeth Husar (Author), Sara Colombetti (Author), Erwin Van Puijenbroek (Author), Markus Neubauer (Author), J. Mark Cline (Author), Pradeep K. Garg (Author), Gregory Dugan (Author), Federica Cavallo (Author), Gonzalo Acuna (Author), Jehad Charo (Author), Volker Teichgräber (Author), Stefan Evers (Author), Otto C. Boerman (Author), Marina Bacac (Author), Ekkehard Moessner (Author), Pablo Umaña (Author), Christian Klein (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and abolished binding to IL-2 Rα. Here, we investigated the immunostimulatory properties of F...